Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaLisa Zimmer, Dirk Schadendorf, Elisabeth Livingstone et al.|PLoS ONE|2015Cited by 292
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Jochen Utikal, Elisabeth Livingstone et al.|The Lancet|2020Cited by 242
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trialElisabeth Livingstone, Patrick Terheyden, Lisa Zimmer et al.|The Lancet|2022Cited by 113
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trialJürgen C. Becker, Lucie Heinzerling, Selma Ugurel et al.|The Lancet|2023Cited by 75
Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.Lisa Zimmer, Dirk Schadendorf, Thomas Eigentler et al.|Journal of Clinical Oncology|2014Cited by 8